Adalvo and JAMP Pharma team up to launch Pomalidomide Hard Capsules in Canada

Adalvo is excited to announce the launch of Pomalidomide Hard Capsules 1/2/3/4mg in Canada.

Adalvo is excited to announce the launch of Pomalidomide Hard Capsules 1/2/3/4mg in Canada.

Our product is based on the reference brand, Pomalyst, and is indicated in the treatment of adult patients with multiple myeloma.


Pomalidomide Hard Capsules 1/2/3/4mg has been launched in collaboration with our strategic partner JAMP Pharma, a Canadian pharmaceutical group with over 35 years of experience. JAMP Pharma is committed to supporting healthcare professionals so that they may focus on what matters most: the well-being of patients.


This effective collaboration has allowed Adalvo to successfully implement a clearly defined IP pathway and provide the opportunity to be amongst the first wave of generic launches for this high-value, oncology product in Canada. This success story is a testament to the exceptional collaboration between Adalvo and JAMP Pharma.


Anil Okay, CEO of Adalvo, states," This momentous achievement signifies Adalvo's commitment to delivering accessible and effective healthcare solutions towards the Oncology segment. By joining forces with JAMP Pharma, a trusted leader in the Canadian pharmaceutical industry, Adalvo are dedicated to making a meaningful difference in the lives of patients and further solidifying our position in the global market"


“We are delighted to introduce PrJAMP Pomalidomide in the Canadian market and therefore, solidify our leading position in the specialty market segment”, states Louis Pilon, CEO of JAMP Pharma Group. “Adalvo has been a keen collaborator in this new product launch, not only from a technical knowhow perspective, but also in sharing a common commitment to positively impact the lives of patients.”